Literature DB >> 32105505

Immunotherapy-related adverse effects on 18F-FDG PET/CT imaging.

Nemi Gandy1, Mubarik A Arshad2, Kathryn L Wallitt1,2, Suraiya Dubash3,4, Sameer Khan2, Tara D Barwick2,4.   

Abstract

18F-Fluorodeoxyglucose positron emission tomography/CT imaging plays a key role in oncological imaging including in staging, radiotherapy planning, treatment response and recurrence assessment. Immunotherapies represent a major advance in cancer therapy for a number of tumours with resulting survival benefit. However, a wide range of immune related adverse events (irAEs), some of which can be apparent on imaging, have been reported. These involve many organ systems but particularly endocrine, cutaneous and gastrointestinal systems. Early detection of irAEs is essential to aid diagnosis and management of patients and to reduce associated morbidity. In addition, it is important to not mistake treatment related effects for disease.This pictorial review aims to identify common irAEs and changes seen on 18F-fluorodeoxyglucose positron emission tomography/CT.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32105505      PMCID： PMC7336053          DOI： 10.1259/bjr.20190832

Source DB:  PubMed          Journal:  Br J Radiol        ISSN： 0007-1285            Impact factor:   3.039


  29 in total

1.  Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean-Jacques Grob; Piotr Rutkowski; Christopher D Lao; C Lance Cowey; Dirk Schadendorf; John Wagstaff; Reinhard Dummer; Pier F Ferrucci; Michael Smylie; David Hogg; Andrew Hill; Ivan Márquez-Rodas; John Haanen; Massimo Guidoboni; Michele Maio; Patrick Schöffski; Matteo S Carlino; Céleste Lebbé; Grant McArthur; Paolo A Ascierto; Gregory A Daniels; Georgina V Long; Lars Bastholt; Jasmine I Rizzo; Agnes Balogh; Andriy Moshyk; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2019-09-28       Impact factor: 91.245

2.  PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course.

Authors:  Mizuki Nishino; Nikhil H Ramaiya; Mark M Awad; Lynette M Sholl; Jennifer A Maattala; Myriam Taibi; Hiroto Hatabu; Patrick A Ott; Philippe F Armand; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2016-08-17       Impact factor: 12.531

3.  Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab.

Authors:  Sree Harsha Tirumani; Nikhil H Ramaiya; Abhishek Keraliya; Nancy D Bailey; Patrick A Ott; F Stephen Hodi; Mizuki Nishino
Journal:  Cancer Immunol Res       Date:  2015-06-22       Impact factor: 11.151

Review 4.  Management of toxicities of immune checkpoint inhibitors.

Authors:  Lavinia Spain; Stefan Diem; James Larkin
Journal:  Cancer Treat Rev       Date:  2016-02-06       Impact factor: 12.111

Review 5.  Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.

Authors:  Bruce D Cheson; Stephen Ansell; Larry Schwartz; Leo I Gordon; Ranjana Advani; Heather A Jacene; Axel Hoos; Sally F Barrington; Philippe Armand
Journal:  Blood       Date:  2016-08-29       Impact factor: 22.113

6.  Metformin Discontinuation prior to FDG PET/CT: A Randomized Controlled Study to Compare 24- and 48-hour Bowel Activity.

Authors:  Ramin Hamidizadeh; Arash Eftekhari; E Ashley Wiley; Don Wilson; Tina Alden; François Bénard
Journal:  Radiology       Date:  2018-08-14       Impact factor: 11.105

Review 7.  Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.

Authors:  L Khoja; D Day; T Wei-Wu Chen; L L Siu; A R Hansen
Journal:  Ann Oncol       Date:  2017-10-01       Impact factor: 32.976

Review 8.  Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician.

Authors:  S Lheureux; C Denoyelle; P S Ohashi; J S De Bono; F M Mottaghy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-10       Impact factor: 9.236

Review 9.  Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy.

Authors:  Gerlig Widmann; Van Anh Nguyen; Julian Plaickner; Werner Jaschke
Journal:  Curr Radiol Rep       Date:  2017-09-11

Review 10.  FDG PET/CT for assessing tumour response to immunotherapy : Report on the EANM symposium on immune modulation and recent review of the literature.

Authors:  Nicolas Aide; Rodney J Hicks; Christophe Le Tourneau; Stéphanie Lheureux; Stefano Fanti; Egesta Lopci
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-05       Impact factor: 9.236
View more
  8 in total

1.  Diagnostic impact of 18F-FDG PET/CT imaging on the detection of immune-related adverse events in patients treated with immunotherapy.

Authors:  Gamze Tatar; Göksel Alçin; Nilay Sengul Samanci; Özge Erol Fenercioglu; Ediz Beyhan; Tevfik Fikret Cermik
Journal:  Clin Transl Oncol       Date:  2022-05-20       Impact factor: 3.340

Review 2.  Gastrointestinal adverse events of immunotherapy.

Authors:  Giovanni Cappello; Francesca Molea; Delia Campanella; Francesca Galioto; Filippo Russo; Daniele Regge
Journal:  BJR Open       Date:  2021-10-20

Review 3.  PET-CT in Clinical Adult Oncology-V. Head and Neck and Neuro Oncology.

Authors:  Richard H Wiggins; John M Hoffman; Gabriel C Fine; Matthew F Covington; Ahmed Ebada Salem; Bhasker R Koppula; Kathryn A Morton
Journal:  Cancers (Basel)       Date:  2022-05-31       Impact factor: 6.575

Review 4.  FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls.

Authors:  Steve Y Cho; Daniel T Huff; Robert Jeraj; Mark R Albertini
Journal:  Semin Nucl Med       Date:  2020-06-28       Impact factor: 4.446

Review 5.  PET-CT in Clinical Adult Oncology-VI. Primary Cutaneous Cancer, Sarcomas and Neuroendocrine Tumors.

Authors:  Gabriel C Fine; Matthew F Covington; Bhasker R Koppula; Ahmed Ebada Salem; Richard H Wiggins; John M Hoffman; Kathryn A Morton
Journal:  Cancers (Basel)       Date:  2022-06-08       Impact factor: 6.575

6.  18 F-FDG PET/CT features of immune-related adverse events and pitfalls following immunotherapy.

Authors:  Martin H Cherk; David P Nadebaum; Thomas W Barber; Paul Beech; Andrew Haydon; Kenneth S Yap
Journal:  J Med Imaging Radiat Oncol       Date:  2022-02-22       Impact factor: 1.667

7.  Prognostic value of immunotherapy-induced organ inflammation assessed on 18FDG PET in patients with metastatic non-small cell lung cancer.

Authors:  Olivier Humbert; Matteo Bauckneht; Jocelyn Gal; Marie Paquet; David Chardin; David Rener; Aurelie Schiazza; Carlo Genova; Renaud Schiappa; Lodovica Zullo; Giovanni Rossi; Nicolas Martin; Florent Hugonnet; Jacques Darcourt; Silvia Morbelli; Josiane Otto
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-05-14       Impact factor: 10.057

8.  Early post-treatment 18F-FDG PET/CT for predicting radiation-induced hypothyroidism in head and neck cancer.

Authors:  Hsi-Huei Lu; Nan-Tsing Chiu; Mu-Hung Tsai
Journal:  Cancer Imaging       Date:  2022-10-10       Impact factor: 5.605
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.